Horae Gene Therapy Center, UMass Chan Medical School, Worcester, Massachusetts, USA.
Department of Microbiology and Physiological Systems, UMass Chan Medical School, Worcester, Massachusetts, USA.
Hum Gene Ther. 2022 Apr;33(7-8):371-388. doi: 10.1089/hum.2022.050.
In the past two decades, adeno-associated virus (AAV) vector manufacturing has made remarkable advancements to meet large-scale production demands for preclinical and clinical trials. In addition, AAV vectors have been extensively studied for their safety and efficacy. In particular, the presence of empty AAV capsids and particles containing "inaccurate" vector genomes in preparations has been a subject of concern. Several methods exist to separate empty capsids from full particles; but thus far, no single technique can produce vectors that are free of empty or partial (non-unit length) capsids. Unfortunately, the exact genome compositions of full, intermediate, and empty capsids remain largely unknown. In this work, we used AAV-genome population sequencing to explore the compositions of DNase-resistant, encapsidated vector genomes produced by two common production pipelines: plasmid transfection in human embryonic kidney cells (pTx/HEK293) and baculovirus expression vectors in insect cells (rBV/Sf9). Intriguingly, our results show that vectors originating from the same construct design that were manufactured by the rBV/Sf9 system produced a higher degree of truncated and unresolved species than those generated by pTx/HEK293 production. We also demonstrate that empty particles purified by cesium chloride gradient ultracentrifugation are not truly empty but are instead packaged with genomes composed of a single truncated and/or unresolved inverted terminal repeat (ITR). Our data suggest that the frequency of these "mutated" ITRs correlates with the abundance of inaccurate genomes in all fractions. These surprising findings shed new light on vector efficacy, safety, and how clinical vectors should be quantified and evaluated.
在过去的二十年中,腺相关病毒(AAV)载体制造取得了显著进展,以满足临床前和临床试验的大规模生产需求。此外,AAV 载体的安全性和有效性也得到了广泛研究。特别是,制剂中存在空 AAV 衣壳和含有“不准确”载体基因组的颗粒一直是人们关注的问题。有几种方法可以将空衣壳与完整颗粒分离;但迄今为止,没有一种单一的技术可以生产出不含空衣壳或部分(非单位长度)衣壳的载体。不幸的是,完整、中间和空衣壳的准确基因组组成在很大程度上仍然未知。在这项工作中,我们使用 AAV 基因组群体测序来探索两种常见生产工艺产生的耐 DNA 酶、包裹的载体基因组的组成:人胚肾细胞中的质粒转染(pTx/HEK293)和昆虫细胞中的杆状病毒表达载体(rBV/Sf9)。有趣的是,我们的结果表明,由 rBV/Sf9 系统制造的源自相同构建体设计的载体比由 pTx/HEK293 生产的载体产生更高程度的截断和未解决的物种。我们还证明,通过氯化铯梯度超速离心纯化的空颗粒实际上并不是空的,而是包装有由单个截断和/或未解决的反向末端重复(ITR)组成的基因组。我们的数据表明,这些“突变”ITR 的频率与所有级分中不准确基因组的丰度相关。这些令人惊讶的发现为载体功效、安全性以及临床载体应如何定量和评估提供了新的视角。